Clinical Trial Update: Anthrax-rPA: Safety, Tolerability, Immunogenicity [Phase 1]

View source ↗

Summary

Phase 1 trial of Anthrax-rPA evaluated safety, tolerability, and immunogenicity and has completed, reporting early safety and immune response data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthrax

Drugs mentioned

• Anthrax-rPA (recombinant protective antigen vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Anthrax | Phase 1 | Status: COMPLETED